Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Schwarz Coping With Omeprazole Competition; Parcopa Is Next Launch

  • News

Executive Summary

Schwarz' levodopa/carbidopa rapid dissolve formulation Parcopa will be the company's first attempt to convert its omeprazole windfall into a larger presence in the U.S. market

You may also be interested in...



Omeprazole Competition: Schwarz Offers Retroactive Discounts

Schwarz Pharma is responding to competition in the generic omeprazole market by offering retroactive discounts to wholesalers on its generic version of AstraZeneca's Prilosec

Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market

Novartis' Lek generic division is following Mylan with an "at risk" launch of generic omeprazole

Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold

Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS042760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By